The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Novo Nordisk CEO Mike Doustdar tells CNBC he expects to close the company's takeover offer for Metsera. This as the company ...

Tokyo's benchmark Nikkei 225 index has fallen more than 4% and other shares in Asia also sank after a retreat on Wall Street ...

Eli Lilly and Novo Nordisk are expected to announce deals with the White House to offer the lowest dose of their weight-loss ...

Eli Lilly and Novo Nordisk are expected to announce deals with the Trump administration to cut prices of their weight-loss ...

Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of ...

Global stocks mostly fell Tuesday as investors weighed the recent tech rally on Wall Street against growing fears of an AI ...

Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera.

A Delaware judge said on Tuesday she did not see in a preliminary evaluation the need to involve the court in the bidding war ...

Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the ...

Jurors heard attorneys’ opening statements on Tuesday for Sean Charles Dunn’s trial in Washington, D.C. on a misdemeanor assault charge.

The fall COVID-19 vaccine season is starting slowly for Pfizer, with U.S. sales of its Comirnaty shots sinking 25% after ...